Market Research Logo

Metabolic Disorders Drugs Market Global Report 2017 Including: Anti-Diabetics, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)Covering: Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, and AstraZeneca PLC

Metabolic Disorders Drugs Market Global Report 2017 Including: Anti-Diabetics, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)Covering: Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, and AstraZeneca PLC

Strategic acquisitions of small companies by market leaders in the market to strengthen their market position is one of the major trend in the metabolic disorders drugs market. For instance, in August 2015 Novo Nordisk acquired Calibrium LLC and MB2 LLC, a US based biopharmaceutical research companies.

The Metabolic Disorders Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorders drugs sector.

Reasons to Purchase

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Gain a global perspective on the development of the market.
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the metabolic disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolic disorders drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
  • The metabolic disorders drugs market section of the report gives context. It compares the metabolic disorders drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Metabolic Disorders Drugs Indicators Comparison.
  • The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope

Markets Covered: Anti-Diabetics, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)

Companies Mentioned: Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, and AstraZeneca PLC

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Metabolic Disorders Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Metabolic Disorders Drugs Market Characteristics
2. Metabolic Disorders Drugs Market Size And Growth
2.1. Historic Market Growth
2.1.1. Drivers Of The Market
2.1.2. Restraints On The Market
2.2. Forecast Market Growth
2.2.1. Drivers Of The Market
2.2.2. Restraints On The Market
3. Pestle Analysis
3.1. Political
3.2. Economic
3.3. Social
3.4. Technological
3.5. Legal
3.6. Environmental
4. Metabolic Disorders Drugs Market Customer Information
5. Metabolic Disorders Drugs Market Segmentation
5.1. Global Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
5.2. Global Metabolic Disorders Drugs Market, 2012 - 2020, Historic And Forecast, By Segment
5.3 Global Metabolic Disorders Drugs Market Trends And Strategies
6. Metabolic Disorders Drugs Market Regional And Country Analysis
6.1. Global Metabolic Disorders Drugs Market, 2016, By Region
6.2. Global Metabolic Disorders Drugs Market, 2012 - 2020, Historic And Forecast, By Region
6.3. Metabolic Disorders Drugs Market, 2016, By Country
6.4. Metabolic Disorders Drugs Market, 2012 - 2020, Historic And Forecast, By Country
6.5. Global Pharmaceutical Market Segments, 2016, By Region
6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region
6.7. Global Pharmaceutical Market Segments, 2016, By Country
6.8.Global Pharmaceutical Drugs Market Segments, 2016, By Country
7. Global Metabolic Disorders Drugs Market Comparison With Macro Economic Factors
7.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, Global
7.2. Per Capita Average Metabolic Disorders Drugs Expenditure, Global
8. Metabolic Disorders Drugs Market Comparison With Macro Economic Factors Across Countries
8.1. Metabolic Disorders Drugs Market Size, Percentage Of GDP, By Country
8.2. Per Capita Average Metabolic Disorders Drugs Expenditure, By Country
9. Metabolic Disorders Drugs Market Comparison With Industry Metrics
9.1. Global Number Of Pharmacists, 2016, By Country
9.2. Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
9.3. Global Number Of Pharma Enterprises, 2016, By Country
9.4. Global Metabolic Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
9.5. Global Average Spending On R&D/Product Development, 2016, By Country
9.6. Global Metabolic Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
9.8. Global Metabolic Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
9.9. Prevalent Cases Of Hypertension, 2014, By Country
9.10. Prevalent Cases Of Diabetes, 2015, By Country
9.11. Global Number Of General Practitioners 2016, By Country
9.12. Global Metabolic Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country
10. Asia-Pacific Metabolic Disorders Drugs Market
10.1.1. Asia-Pacific Metabolic Disorders Drugs Market Overview
10.1.2. Asia-Pacific Metabolic Disorders Drugs Historic Market, 2012 - 2016
10.1.3. Asia-Pacific Metabolic Disorders Drugs Forecast Market, 2016 - 2020
10.1.4. Asia-Pacific Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
10.2. Asia-Pacific Metabolic Disorders Drugs Market: Country Analysis
10.3. China Metabolic Disorders Drugs Market
10.3.1. China Metabolic Disorders Drugs Market Overview
10.3.2. China Metabolic Disorders Drugs Historic Market, 2012 - 2016
10.3.3. China Metabolic D4isorders Forecast Market, 2016 - 2020
10.3.4. China Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
10.3.5. China Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
10.3.6. China Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
10.4. India Metabolic Disorders Drugs Market
10.4.1. India Metabolic Disorders Drugs Market Overview
10.4.2. India Metabolic Disorders Drugs Historic Market, 2012 - 2016
10.4.3. India Metabolic Disorders Drugs Forecast Market, 2016 - 2020
10.4.4. India Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
10.4.5. India Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
10.4.6. India Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
10.5. Japan Metabolic Disorders Drugs Market
10.5.1. Japan Metabolic Disorders Drugs Market Overview
10.5.2. Japan Metabolic Disorders Drugs Historic Market, 2012 - 2016
10.5.3. Japan Metabolic Disorders Drugs Forecast Market, 2016 - 2020
10.5.4. Japan Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
10.5.5. Japan Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
10.5.6. Japan Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
10.6. Australia Metabolic Disorders Drugs Market
10.6.1. Australia Metabolic Disorders Drugs Historic Market, 2012 - 2016
10.6.2. Australia Metabolic Disorders Drugs Forecast Market, 2016 - 2020
10.6.3. Australia Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
10.6.4. Australia Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
10.6.5. Australia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
11. Western Europe Metabolic Disorders Drugs Market
11.1.1. Western Europe Metabolic Disorders Drugs Market Overview
11.1.2. Western Europe Metabolic Disorders Drugs Historic Market, 2012 - 2016
11.1.3. Western Europe Metabolic Disorders Drugs Forecast Market, 2016 - 2020
11.1.4. Western Europe Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
11.2. Western Europe Metabolic Disorders Drugs Market: Country Analysis
11.3. UK Metabolic Disorders Drugs Market
11.3.1. UK Metabolic Disorders Drugs Market Overview
11.3.2. UK Metabolic Disorders Drugs Historic Market, 2012 - 2016
11.3.3. UK Metabolic Disorders Drugs Forecast Market, 2016 - 2020
11.3.4. UK Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
11.3.5. UK Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
11.3.6. UK Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
11.4. Germany Metabolic Disorders Drugs Market
11.4.1. Germany Metabolic Disorders Drugs Historic Market, 2012 - 2016
11.4.2. Germany Metabolic Disorders Drugs Forecast Market, 2016 - 2020
11.4.3. Germany Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
11.4.4 Germany Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
11.4.5 Germany Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
11.5 France Metabolic Disorders Drugs Market
11.5.1 France Metabolic Disorders Drugs Historic Market, 2012 - 2016
11.5.2 France Metabolic Disorders Drugs Forecast Market, 2016 - 2020
11.5.3 France Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
11.5.4 France Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
11.5.5 France Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
11.6. Italy Metabolic Disorders Drugs Market
11.6.1. Italy Metabolic Disorders Drugs Historic Market, 2012 - 2016
11.6.2. Italy Metabolic Disorders Drugs Forecast Market, 2016 - 2020
11.6.3. Italy Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
11.6.4. Italy Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
11.6.5. Italy Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
11.7. Spain Metabolic Disorders Drugs Market
11.7.1. Spain Metabolic Disorders Drugs Historic Market, 2012 - 2016
11.7.2. Spain Metabolic Disorders Drugs Forecast Market, 2016 - 2020
11.7.3. Spain Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
11.7.4. Spain Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
11.7.5. Spain Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
12. Eastern Europe Metabolic Disorders Drugs Market
12.1.1. Eastern Europe Metabolic Disorders Drugs Market Overview
12.1.2. Eastern Europe Metabolic Disorders Drugs Historic Market, 2012 - 2016
12.1.3. Eastern Europe Metabolic Disorders Drugs Forecast Market, 2016 - 2020
12.1.4 Eastern Europe Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
12.2. Eastern Europe Metabolic Disorders Drugs Market: Country Analysis
12.3. Russia Metabolic Disorders Drugs Market
12.3.1. Russia Metabolic Disorders Drugs Historic Market, 2012 - 2016
12.3.2. Russia Metabolic Disorders Drugs Forecast Market, 2016 - 2020
12.3.3. Russia Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
12.3.4. Russia Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
12.3.5. Russia Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
13. North America Metabolic Disorders Drugs Market
13.1.1. North America Metabolic Disorders Drugs Market Overview
13.1.2. North America Metabolic Disorders Drugs Historic Market, 2012 - 2016
13.1.3. North America Metabolic Disorders Drugs Forecast Market, 2016 - 2020
13.1.4. North America Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
13.2. North America Metabolic Disorders Drugs Market: Country Analysis
13.3. USA Metabolic Disorders Drugs Market
13.3.1. USA Metabolic Disorders Drugs Historic Market, 2012 - 2016
13.3.2. USA Metabolic Disorders Drugs Forecast Market, 2016 - 2020
13.3.3 USA Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
13.3.4. USA Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
13.3.5. USA Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
14. South America Metabolic Disorders Drugs Market
14.1.1. South America Metabolic Disorders Drugs Market Overview
14.1.2. South America Metabolic Disorders Drugs Historic Market, 2012 - 2016
14.1.3. South America Metabolic Disorders Drugs Forecast Market, 2016 - 2020
14.1.4. South America Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
14.2. South America Metabolic Disorders Drugs Market: Country Analysis
14.3. Brazil Metabolic Disorders Drugs Market
14.3.1. Brazil Metabolic Disorders Drugs Historic Market, 2012 - 2016
14.3.2. Brazil Metabolic Disorders Drugs Forecast Market, 2016 - 2020
14.3.3. Brazil Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
14.3.4. Brazil Metabolic Disorders Drugs Percentage Of GDP, 2012 - 2020
14.3.5. Brazil Per Capita Average Metabolic Disorders Drugs Expenditure, 2012 - 2020
15. Middle East Metabolic Disorders Drugs Market
15.1.1. Middle East Metabolic Disorders Drugs Market Overview
15.1.2. Middle East Metabolic Disorders Drugs Historic Market, 2012 - 2016
15.1.3. Middle East Metabolic Disorders Drugs Forecast Market, 2016 - 2020
15.1.4. Middle East Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
16. Africa Metabolic Disorders Drugs Market
16.1.1. Africa Metabolic Disorders Drugs Market Overview
16.1.2. Africa Metabolic Disorders Drugs Historic Market, 2012 - 2016
16.1.3. Africa Metabolic Disorders Drugs Forecast Market, 2016 - 2020
16.1.4. Africa Metabolic Disorders Drugs Market, 2016, By Segment
Anti-Diabetics
Anti-Thyroid Drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
17. Metabolic Disorders Drugs Market Competitive Landscape
17.1. Company Profiles
17.2. Novo Nordisk
17.2.1. Overview
17.2.2. Products And Services
17.2.3. Strategy
17.2.4. Financial Performance
17.3. Sanofi
17.3.1. Overview
17.3.2. Products And Services
17.3.3. Strategy
17.3.4. Financial Performance
17.4. Merck & Co.
17.4.1. Overview
17.4.2. Products And Services
17.4.3. Strategy
17.4.4. Financial Performance
17.5. Eli Lilly
17.5.1. Overview
17.5.2. Products And Services
17.5.3. Strategy
17.5.4. Financial Performance
17.6. Astrazeneca PLC
17.6.1. Overview
17.6.2. Products And Services
17.6.3. Strategy
17.6.4. Financial Performance
18. Key Mergers And Acquisitions In The Metabolic Disorders Drugs Market
19. Market Background: Pharmaceutical Drugs Market
19.1.1. Pharmaceutical Drugs Market Characteristics
19.1.2. Pharmaceutical Drugs Market Historic Growth
19.1.2.1. Drivers Of The Market
19.1.2.2. Restraints Of The Market
19.1.3. Pharmaceutical Drugs Market Forecast Growth
19.1.3.1. Drivers Of The Market
19.1.3.2. Restraints Of The Market
19.1.4. Pharmaceutical Drugs Trends And Strategies
19.2. Pharmaceutical Drugs Market Regional And Country Analysis
19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region
19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region
19.2.3. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country
19.2.4. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors
19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global
19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country
19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market
20. Pharmaceuticals Industry Financial Margins
21. Appendix
21.1. NAICS Definitions Of Industry Covered In This Report
21.2. Abbreviations
21.3. Currencies
21.4. Research Inquiries
21.5. The Business Research Company
21.6. Copyright And Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report